Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
Faculty of Health Sciences, University of Copenhagen and the Pediatric Clinic, Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark.
J Adv Nurs. 2018 Jan;74(1):110-118. doi: 10.1111/jan.13407. Epub 2017 Sep 10.
To explore parents' and adolescents' motives for accepting/declining participation in the ALL2008 trials and adolescents' involvement in the decision-making process.
Children and adolescents with acute lymphoblastic leukaemia treated on the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol were eligible for two randomizations testing 6-mercaptopurine treatment intensifications to improve efficacy and Asparaginase de-escalation to reduce toxicity. We recently reported that while adolescents favoured treatment reduction, parents of young children favoured treatment intensification.
A qualitative, exploratory study.
A maximum variation sampling strategy was used. Five adolescents aged 12-17 years, six parents of adolescents and five parents of children aged 1-12 years were interviewed in the period March-May 2015. Data were analysed using content analysis.
Adolescents and parents emphasized the importance of adolescents' active participation in decisions regarding enrolment into clinical trials. A majority of adolescents were either final or collaborative decision-makers. Parents stated that in case of disagreement, they would overrule the adolescents' decision. There were no differences between motivations of preferences held by parents of children or adolescents, respectively. Decisions were based on subjective values attributed to cure contra toxicity and individual preferences for either standard or experimental treatment. The possibility of a negative outcome induced fear of decisional regret and distress by the parents, yet they invested considerable trust in the physician's expertise.
Our findings highlight the importance of adolescents' active involvement in consent conferences. Research on management of disagreements between adolescents and parents in trial decisions is needed.
探讨父母同意/拒绝参与 ALL2008 试验的动机,以及青少年在决策过程中的参与度。
在北欧儿科血液学和肿瘤学会 ALL2008 方案中治疗的急性淋巴细胞白血病儿童和青少年有资格参加两项随机分组试验,以测试强化 6-巯基嘌呤治疗以提高疗效和降低天冬酰胺酶剂量以减少毒性。我们最近报告称,尽管青少年赞成减少治疗,但幼儿的父母则赞成强化治疗。
定性、探索性研究。
采用最大变异抽样策略。2015 年 3 月至 5 月期间,对 5 名 12-17 岁的青少年、6 名青少年的父母和 5 名 1-12 岁儿童的父母进行了访谈。使用内容分析法分析数据。
青少年和父母都强调了青少年在参与临床试验入组决策方面的积极参与的重要性。大多数青少年是最终或合作决策者。父母表示,如果意见不一致,他们将否决青少年的决定。儿童和青少年父母的偏好动机没有差异。决策基于治愈与毒性的主观价值和对标准或实验治疗的个人偏好。负面结果的可能性引起了父母的决策后悔和担忧的恐惧,但他们对医生的专业知识给予了相当大的信任。
我们的研究结果强调了青少年在同意会议中积极参与的重要性。需要研究在试验决策中处理青少年和父母之间意见分歧的方法。